Shuttle Pharma begins Phase 2 glioblastoma trial; regains Nasdaq compliance

Shuttle Pharmaceuticals Holdings, Inc.

Phase 2 trial of Ropidoxuridine for glioblastoma opened at two sites; four more anticipated this month.
40 patients initially randomized to 1,200 mg/day or 960 mg/day; then 14 more on optimal dose.
FDA Orphan Drug Designation granted for Ropidoxuridine; potential marketing exclusivity.
Nasdaq non-compliance resolved after filing re-audited financials and delayed Q2 2023 10-Q.
Trial expected to complete in 18-24 months; primary endpoint survival vs historical controls.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.